Status:
UNKNOWN
Safety and Efficacy of Different Antiviral Regimens for Hepatitis C Virus Relapse
Lead Sponsor:
Alexandria University
Conditions:
Hepatitis C
Relapse
Eligibility:
All Genders
18+ years
Brief Summary
The primary goal of hepatitis C virus (HCV) Direct Acting Antivirals (DAAs) is to achieve undetectable HCV RNA in the blood. A response that should be maintained for at least 12 weeks from completion ...
Eligibility Criteria
Inclusion
- all patients with HCV relapse after sofosbuvir plus either Non-structural protein 5 A (NS5A) or protease inhibitor.
Exclusion
- No exclusion criteria
Key Trial Info
Start Date :
August 24 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
May 28 2022
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT04662138
Start Date
August 24 2020
End Date
May 28 2022
Last Update
December 10 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Alexandria University.
Alexandria, Egypt, 21131